



Maze Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 5, 2022

SOUTH SAN FRANCISCO, CA, January 5, 2022 – Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that Jason Coloma, Ph.D, president and chief executive officer of Maze, will present a company overview at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at 1:30 p.m. ET.

About Maze Therapeutics

Maze Therapeutics is focused on translating genetic insights into new precision medicines for patients with rare diseases and mechanistically defined subsets of common diseases. Maze has developed the MAZE COMPASSTM platform, a proprietary, purpose-built platform that combines human genetic data, functional genomic tools and data science technology to map novel connections between known genes and their influence on susceptibility, timing of onset and rate of disease progression. Using COMPASS, Maze is building a broad portfolio, including wholly owned programs targeting Pompe disease, chronic kidney disease and amyotrophic lateral sclerosis, as well as partnered programs in cardiovascular and ophthalmic diseases. Maze is based in South San Francisco. For more information, please visit mazetx.com, or follow us on LinkedIn.

Contacts:

Investors:

Jillian Connell, Maze Therapeutics
jconnell@mazetx.com
650.850.5080

Media:

Katie Engleman, 1AB
katie@1abmedia.com